GenSight Biologics Reports Cash Position as of June 30, 2024, and Provides Business Update

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of June 30, 2024, and provided a business update. “As a result of our continuing financial discipline, GenSight Biologics is well-positioned to continue to advance towards our objec